Allergan AGN announces its next round of earnings this Tuesday, Jan. 29. Here is Benzinga's everything-that-matters guide for the Q4 earnings announcement.
Earnings and Revenue
Wall Street expects EPS of $4.15 and sales around $4.00 billion.
Allergan reported a per-share profit of $4.86 when it published results during the same quarter last year. Sales in that period totaled $4.33 billion. The analyst consensus estimate would represent a 14.61 percent decrease in the company's earnings. Revenue would be down 7.54 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | 4.02 | 4.12 | 3.36 | 4.73 |
| EPS Actual | 4.25 | 4.42 | 3.74 | 4.86 |
Stock Performance
Over the last 52-week period, shares are down 13.96 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The average rating by analysts on Allergan stock is a Neutral. The validity of this rating has maintained conviction over the past 90 days.
Conference Call
Allergan's Q4 conference call is scheduled to begin at 8:30 a.m. ET and can be accessed here: https://edge.media-server.com/m6/p/ws8rp2uc
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
